Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity.
This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.
Age ≥65 years
Histologically confirmed stage IV NSCLC
Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion
Treated with at least ONE cycle of first-line chemotherapy
Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting
Incomplete survival data
Retrospective cohort study using data from three centres in Malaysia from 2020 to 2025. All patients aged ≥65 years with advanced/metastatic NSCLC and no actionable driver mutations who received AT LEAST ONE CYCLE of first-line chemotherapy will be included in the analysis.
Cohort
Retrospective
Progression free survival
Other interventionPFS
Overall survival
Other interventionOS
To compare the overall survival (OS) between older NSCLC patients treated with standard-dose versus reduced-dose first-line platinum-doublet chemotherapy OR single agent non-platinum chemotherapy.
To compare the progression free survival (PFS) between older NSCLC patients treated with standard-dose versus reduced-dose first-line platinum-doublet chemotherapy OR single agent non-platinum chemotherapy.
To assess objective response rates in patients who complete FOUR cycles of chemotherapy.
Click on the lead sponsor to view all of their trials.
